University of Pittsburgh Cancer Institute gets NCI preclinical research contract

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

THE UNIVERSITY OF PITTSBURGH CANCER INSTITUTE, partnered with UPMC CancerCancer, received a contract from NCI to perform preclinical research for the development of new cancer drugs. This commitment could bring up to $10 million in research projects to UPCI over the next five years.

Julie Eiseman, professor of pharmacology and chemical biology, and Jan Beumer, associate professor of pharmaceutical sciences and medicine, will serve as co-principal investigators on the research contract. They also hold a previous NCI preclinical contract, which will conclude next year. The researchers do not yet know specifically what potential drugs they’ll be investigating or in which indications.

YOU MAY BE INTERESTED IN

Candace S. Johnson leads America’s oldest cancer research center and Jonathan W. Friedberg leads the newest NCI-designated center. Their catchment areas are contiguous, their faculty and staff members collaborate often, and together their institutions embody the culture of NCI-designated cancer centers. 

In the first meeting of the National Cancer Advisory Board since the inauguration of President Donald Trump, NCI Principal Deputy Director Douglas R. Lowy addressed many of the burning questions the oncology field has for the institute. On indirect costs: NCI will continue to use previously negotiated and approved indirect cost rates, with the exception...

The Cancer Letter staff were finalists for nine 2025 Dateline Awards from the Washington, D.C. Chapter of the Society of Professional Journalists—seven for journalism; two for design—and won first place for four. The Cancer Letter’s entries recognized by SPJ include investigative journalism, series, breaking news, features, photojournalism, commentary, illustration, and front page design. This is...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login